Drug firm Lupin today said it has received approval from the US health regulator for Hydroxychloroquine Sulfate tablets, which is used to treat malaria.
The company has received final approval from the USFDA for its product which is a generic version of Concordia Pharmaceuticals, Inc's Plaquenil tablets, Lupin said in a statement.
The drug is indicated for the treatment of malaria and acute and chronic rheumatoid arthritis in adults.
According to IQVIA MAT April 2018 data, Hydroxychloroquine Sulfate tablets had annual sales of around USD 215.3 million in the US.
Shares of Lupin today ended 0.42 per cent down at Rs 911.95 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)